Aadi Bioscience Leads 3 Promising US Penny Stocks

As the U.S. stock market navigates a challenging week marked by encouraging inflation data yet overall losses, investors are exploring diverse opportunities to mitigate risk and capitalize on potential gains. Penny stocks, often associated with smaller or newer companies, continue to attract attention due to their potential for significant returns when backed by strong financial health. Despite being considered a niche area of investment today, these stocks can offer intriguing opportunities for those willing to explore beyond traditional large-cap options.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
QuantaSing Group (NasdaqGM:QSG)	$3.08	$99.16M	★★★★★★
Inter & Co (NasdaqGS:INTR)	$4.36	$1.91B	★★★★☆☆
BAB (OTCPK:BABB)	$0.89	$6.46M	★★★★★★
Pangaea Logistics Solutions (NasdaqCM:PANL)	$4.84	$227.01M	★★★★★☆
ZTEST Electronics (OTCPK:ZTST.F)	$0.2109	$7.76M	★★★★★★
Imperial Petroleum (NasdaqCM:IMPP)	$2.84	$86.14M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$67.38M	★★★★★★
Smith Micro Software (NasdaqCM:SMSI)	$0.9694	$17.19M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$0.78	$70.15M	★★★★★☆
Safe Bulkers (NYSE:SB)	$3.51	$374.79M	★★★★☆☆

Click here to see the full list of 741 stocks from our US Penny Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Aadi Bioscience (NasdaqCM:AADI)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Aadi Bioscience, Inc. is a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, with a market cap of $83.55 million.

Operations: The company's revenue segment is focused on developing and commercializing proprietary therapeutics, generating $25.07 million.

Market Cap: $83.55M

Aadi Bioscience, Inc. recently secured an exclusive license agreement to develop and commercialize a portfolio of preclinical antibody-drug conjugates (ADCs) with WuXi Biologics and Hangzhou DAC Biotechnology. Despite its strategic advancements, Aadi remains unprofitable, with losses increasing over the past five years and no profitability forecast in the near term. The company reported US$18.74 million in revenue for the first nine months of 2024 but continues to incur significant net losses. While its short-term assets cover liabilities comfortably, Aadi's share price has been highly volatile, reflecting inherent risks associated with penny stocks in the biotech sector.

• Get an in-depth perspective on Aadi Bioscience's performance by reading our balance sheet health report here.
• Understand Aadi Bioscience's earnings outlook by examining our growth report.

Immuneering (NasdaqGM:IMRX)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Immuneering Corporation is a clinical-stage oncology company focused on developing medicines for broad populations of cancer patients, with a market cap of $62.10 million.

Operations: Immuneering Corporation has not reported any revenue segments.

Market Cap: $62.1M

Immuneering Corporation, a clinical-stage oncology company, remains pre-revenue with a market cap of US$62.10 million and is currently unprofitable, with losses increasing over the past five years. The company's stock has shown significant volatility, though its weekly volatility has decreased from 19% to 14% over the past year. Immuneering's short-term assets of US$55.3 million exceed both its short and long-term liabilities, but it faces a cash runway of less than one year if current cash flow trends persist. Recent developments include FDA Fast Track designation for IMM-1-104 and strategic advisory board formation for pancreatic cancer research guidance.

• Click to explore a detailed breakdown of our findings in Immuneering's financial health report.
• Explore Immuneering's analyst forecasts in our growth report.

Qudian (NYSE:QD)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Qudian Inc. is a consumer-oriented technology company based in the People's Republic of China, with a market cap of $547.38 million.

Operations: The company's revenue is derived from its Installment Credit Services segment, which generated CN¥227.99 million.

Market Cap: $547.38M

Qudian Inc., with a market cap of $547.38 million, has shown some financial resilience despite challenges typical of penny stocks. The company reported third-quarter revenue of CN¥55.02 million, a significant increase from the previous year, alongside a net income turnaround to CN¥131.91 million from a prior loss. Its short-term assets significantly exceed both short and long-term liabilities, indicating strong liquidity management. However, Qudian's earnings have declined sharply over the past five years and its return on equity remains low at 0.4%. Despite reduced debt levels and stable weekly volatility, share price volatility persists in recent months.

• Take a closer look at Qudian's potential here in our financial health report.
• Assess Qudian's previous results with our detailed historical performance reports.

Key Takeaways

• Explore the 741 names from our US Penny Stocks screener here.
• Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
• Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com